Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

Exclusion Criteria

• •Known human immunodeficiency virus (HIV) positive status or known or suspected systemic bacterial, viral, parasitic, or fungal infection;
• •Received an investigational agent, other than tafamidis or diflunisal, within 30 days prior to first dose study drug administration;
• •Prior liver transplant;
• •Poor cardiac function;
• •Considered unfit for the study by the Principal Investigator;
• •Employee or family member of the sponsor or the clinical study site personnel.